Novanta ses Q1 adjusted EPS 64c-65c, consensus 74c

Sees Q1 revenue $210M-$212M, consensus $217.55M. Sees Q1 adjusted EBTDA $44M-$45M. "We remain very optimistic about our position and opportunities in the medical and advanced industrial end markets that we serve," said Matthijs Glastra, CEO, "Sales in our medical end markets are expected to have solid demand in 2023. And despite some near term slowdown in some areas of the microelectronics end market capital spending, we enter the year with strong backlog and resilient customer demand. We are confident in the ability of our teams to remain disciplined and diligent to serve our customers and deliver strong operating performance in the year ahead."